← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Versapeutics Inc
San Diego, CA
$7,005,930
Total funding
6
Grants
Funding over time
peak $2.9M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,005,930 · 6
By mechanism
R44$5,266,509 · 2
R43$1,739,421 · 4
Investigators at Versapeutics Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment$2,380,552
R44 · FY2023 · NS
Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment$1,455,927
R44 · FY2025 · NS
Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment$1,430,030
R44 · FY2024 · NS
Developing therapeutic antibodies for Alzheimer's disease$498,534
R43 · FY2022 · AG
Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury$495,137
R43 · FY2022 · NS
Developing therapeutic antibodies for Alzheimer's disease$489,628
R43 · FY2023 · AG
Preclinical Development of VERSAMAB-101 for Spinal Cord Injury$256,122
R43 · FY2021 · NS